Britannia Life Sciences Inc
CNSX:BLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Britannia Life Sciences Inc
CNSX:BLAB
|
CA |
|
Immo Moury Sicaf Immobiliere Publique de Droit Belge SCA
XBRU:IMMOU
|
BE |
|
G
|
Gav-Yam Lands Corp Ltd
TASE:GVYM
|
IL |
|
B
|
Bezeq Israeli Telecommunication Corp Ltd
TASE:BEZQ
|
IL |
|
Bang & Olufsen A/S
CSE:BO
|
DK |
|
R
|
Ribbon Communications Inc
F:NU42
|
US |
|
Epiroc AB
STO:EPI A
|
SE |
|
C
|
CD Projekt SA
WSE:CDR
|
PL |
|
T
|
Team Inc
NYSE:TISI
|
US |
|
Mahanagar Telephone Nigam Ltd
NSE:MTNL
|
IN |
|
Braze Inc
NASDAQ:BRZE
|
US |
|
M
|
Meridian Bioscience Inc
LSE:0K0K
|
US |
|
Croda International PLC
LSE:CRDA
|
UK |
|
FAT Brands Inc
NASDAQ:FAT
|
US |
Cash Flow Statement
Cash Flow Statement
Britannia Life Sciences Inc
| May-2021 | Aug-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||||||||||
| Net Income |
2
|
4
|
(9)
|
(14)
|
(15)
|
(14)
|
0
|
6
|
2
|
2
|
2
|
(4)
|
(5)
|
(7)
|
(7)
|
(5)
|
(5)
|
(4)
|
7
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
|
| Change in Deffered Taxes |
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
|
| Stock-Based Compensation |
0
|
0
|
0
|
1
|
1
|
2
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Non-Cash Items |
(3)
|
(4)
|
11
|
16
|
18
|
17
|
2
|
(4)
|
(1)
|
(1)
|
(1)
|
5
|
6
|
8
|
8
|
1
|
0
|
(1)
|
(12)
|
|
| Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Change in Working Capital |
1
|
(2)
|
1
|
0
|
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
2
|
|
| Cash from Operating Activities |
(0)
N/A
|
(2)
-571%
|
3
N/A
|
3
+12%
|
3
+5%
|
4
+34%
|
2
-53%
|
1
-34%
|
2
+49%
|
2
-17%
|
1
-6%
|
2
+46%
|
1
-29%
|
1
-33%
|
1
+12%
|
(3)
N/A
|
(4)
-44%
|
(4)
-16%
|
(4)
+7%
|
|
| Investing Cash Flow | ||||||||||||||||||||
| Capital Expenditures |
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
|
| Other Items |
0
|
0
|
1
|
1
|
(2)
|
(2)
|
(3)
|
(3)
|
(0)
|
(0)
|
(1)
|
(1)
|
0
|
0
|
0
|
11
|
11
|
6
|
6
|
|
| Cash from Investing Activities |
0
N/A
|
0
N/A
|
1
N/A
|
1
-2%
|
(2)
N/A
|
(2)
-7%
|
(3)
-30%
|
(3)
-2%
|
(1)
+78%
|
(0)
+35%
|
(1)
-179%
|
(1)
-6%
|
(1)
+22%
|
(1)
-16%
|
(0)
+65%
|
11
N/A
|
11
-1%
|
6
-44%
|
6
+2%
|
|
| Financing Cash Flow | ||||||||||||||||||||
| Net Issuance of Common Stock |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Issuance of Debt |
(2)
|
0
|
(2)
|
(2)
|
1
|
1
|
3
|
3
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
0
|
(0)
|
0
|
|
| Other |
1
|
1
|
(1)
|
(1)
|
0
|
0
|
(1)
|
0
|
0
|
(1)
|
(1)
|
(2)
|
0
|
0
|
0
|
(2)
|
(2)
|
(2)
|
(2)
|
|
| Cash from Financing Activities |
0
N/A
|
2
+2 746%
|
(2)
N/A
|
(3)
-5%
|
0
N/A
|
(0)
N/A
|
2
N/A
|
3
+29%
|
(0)
N/A
|
(1)
-29%
|
(1)
-38%
|
(2)
-126%
|
(2)
-3%
|
(1)
+33%
|
(1)
-7%
|
(2)
-48%
|
(2)
+23%
|
(2)
-13%
|
(1)
+29%
|
|
| Change in Cash | ||||||||||||||||||||
| Effect of Foreign Exchange Rates |
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
|
| Net Change in Cash |
(0)
N/A
|
(0)
+62%
|
1
N/A
|
1
+14%
|
1
+8%
|
1
+40%
|
1
-25%
|
1
+7%
|
1
-16%
|
1
-32%
|
(1)
N/A
|
(1)
-76%
|
(2)
-32%
|
(2)
+9%
|
(1)
+53%
|
7
N/A
|
6
-13%
|
(0)
N/A
|
1
N/A
|
|
| Free Cash Flow | ||||||||||||||||||||
| Free Cash Flow |
(0)
N/A
|
(2)
-571%
|
2
N/A
|
3
+11%
|
3
+5%
|
4
+29%
|
2
-57%
|
1
-45%
|
1
+42%
|
1
-4%
|
1
-2%
|
2
+49%
|
1
-26%
|
1
-52%
|
1
+5%
|
(3)
N/A
|
(4)
-44%
|
(4)
-16%
|
(4)
+7%
|
|